Study on Using a Patient's Own Stem Cells for Treating Lymphoma

Sponsor: Masonic Cancer Center, University of Minnesota

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT03125642

Provider View

This clinical trial is exploring the use of a patient's own stem cells to treat Hodgkin and non-Hodgkin lymphomas, including those who are HIV positive. The study aims to determine if this approach is effective for patients who have not responded to other treatments.

Patient Parameters

Program Overview

This study is testing a treatment that uses a patient's own stem cells to help fight Hodgkin and non-Hodgkin lymphomas, including for patients who are HIV positive. The goal is to see if this method can be effective for those who have not had success with other treatments.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with certain types of non-Hodgkin's Lymphoma (NHL) or Hodgkin Lymphoma (HL) that are sensitive to chemotherapy.
  • NHL patients must be in partial or complete remission after cell therapy, or have specific high-risk features.
  • HL patients must have failed previous treatments and meet certain criteria, such as having high-risk features or bulky disease.
  • HIV positive patients can participate if they are on effective HIV treatment and meet specific health criteria.
  • Must be in good overall health with a performance status score of 80% or higher, or 60% if poor health is due to lymphoma.
  • Must have adequate organ function, including:
    • Blood counts above specific levels.
    • Good kidney and liver function.
    • Heart function with an ejection fraction above 40%.
    • Lung function with FEV1 and DLCO above 50%.
  • Must be at least 4 weeks from previous chemotherapy, or 6 weeks from certain drugs.
  • Women of childbearing potential and sexually active men must agree to use birth control during treatment.
  • Must provide voluntary written consent.

Exclusion Criteria

  • Pregnant or breastfeeding women.
  • Eligible for other higher priority transplant protocols.
  • Have chemotherapy-resistant disease.
  • Have an unrelated active infection.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.